<SEC-DOCUMENT>0001341004-22-000196.txt : 20220823
<SEC-HEADER>0001341004-22-000196.hdr.sgml : 20220823
<ACCEPTANCE-DATETIME>20220822215026
ACCESSION NUMBER:		0001341004-22-000196
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220822
FILED AS OF DATE:		20220823
DATE AS OF CHANGE:		20220822

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALCON INC
		CENTRAL INDEX KEY:			0001167379
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				980205094
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31269
		FILM NUMBER:		221184990

	BUSINESS ADDRESS:	
		STREET 1:		6201 SOUTH FREEWAY
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76134
		BUSINESS PHONE:		817 293 0450

	MAIL ADDRESS:	
		STREET 1:		CHEMIN DE BLANDONNET 8
		STREET 2:		1214 VERNIER
		CITY:			GENEVA
		STATE:			V8
		ZIP:			0000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Skadden Arps
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div><br>
  </div>
  <div>
    <div style="text-align: center; font-family: Times; font-size: 18pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-family: Times; font-size: 18pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: Times; font-weight: bold;">Washington, DC 20549</div>
    <div style="text-align: center; font-family: Times; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; margin-top: 5pt; margin-bottom: 5pt; font-family: Times; font-size: 18pt; font-weight: bold;">Form&#160;6-K</div>
    <div style="text-align: center; font-family: Times; font-size: 12pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: Times; font-size: 12pt; font-weight: bold;">Report of Foreign Private Issuer</div>
    <div style="text-align: center; font-family: Times; font-size: 12pt; font-weight: bold;">Pursuant to Rule&#160;13a-16 or&#160;15d-16 of</div>
    <div style="text-align: center; font-family: Times; font-size: 12pt; font-weight: bold;">the Securities Exchange Act of 1934</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zba620241106044b1ba20737c2cc963b6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 49.03%; vertical-align: bottom;">
            <div style="text-align: center; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman'; font-weight: bold;">August 22, 2022</div>
          </td>
          <td style="width: 1.92%; vertical-align: bottom;">
            <div style="font-family: Times;">&#160;</div>
          </td>
          <td style="width: 49.06%; vertical-align: bottom;">
            <div style="text-align: center; text-indent: -10pt; margin-left: 10pt; font-family: Times; font-weight: bold;">Commission File Number: 001-31269</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; margin-top: 5pt; margin-bottom: 5pt; font-family: Times; font-size: 12pt;"><font style="font-size: 18pt; font-weight: bold;"> <br>
      </font></div>
    <div style="text-align: center; margin-top: 5pt; margin-bottom: 5pt; font-family: Times; font-size: 12pt;"><font style="font-size: 18pt; font-weight: bold;">ALCON INC.</font><br>
      <font style="font-size: 10pt;">(Name of Registrant)</font></div>
    <div style="text-align: center; margin-top: 5pt; margin-bottom: 5pt; font-family: Times; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
      </font></div>
    <div style="text-align: center; font-family: Times; font-weight: bold;">Rue Louis-d'Affry 6 </div>
    <div style="text-align: center; font-family: Times;"><font style="font-weight: bold;">1701 Fribourg, Switzerland</font><br>
      (Address of Principal Executive Offices)</div>
    <div style="text-align: justify; text-indent: 27pt; margin-top: 5pt; margin-bottom: 5pt; font-family: Times;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#160;20-F or Form&#160;40-F:</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf7ccc1d5d70d40aaa276d342ac27affb" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 48.87%; vertical-align: top;">
            <div style="text-align: center; font-family: Times;">Form&#160;20-F &#9746;</div>
          </td>
          <td style="width: 2.24%; vertical-align: top;">
            <div style="font-family: Times;">&#160;</div>
          </td>
          <td style="width: 48.89%; vertical-align: top;">
            <div style="text-align: center; font-family: Times;">Form&#160;40-F &#9744;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; margin-top: 5pt; margin-bottom: 5pt; font-family: Times;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160; &#9744;</div>
    <div style="text-align: justify; margin-top: 5pt; margin-bottom: 5pt; font-family: Times;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T <font style="font-family: 'Times New Roman';">Rule&#160;101(b)(7):&#160;&#160;&#160;

      </font>&#9744;</div>
    <div style="margin-top: 5pt; margin-bottom: 5pt;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman'; font-weight: bold;">EXHIBITS</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zce03b619ffd244508b1ad82987b2077e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15.12%; vertical-align: top; border-bottom: #000000 0.50pt solid;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Exhibit Number</div>
          </td>
          <td style="width: 4.6%; vertical-align: top;">&#160;</td>
          <td style="width: 80.28%; vertical-align: bottom; border-bottom: #000000 0.50pt solid;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15.12%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">99.1</div>
          </td>
          <td style="width: 4.6%; vertical-align: top;">&#160;</td>
          <td style="width: 80.28%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Press release issued by Alcon Inc. dated August 22, 2022 titled &#8220;Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter">
        <div><br>
        </div>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; margin-top: 5pt; margin-bottom: 5pt; font-family: Times; font-weight: bold;">SIGNATURE</div>
    <div style="text-align: justify; text-indent: 36pt; margin-top: 5pt; margin-bottom: 5pt; font-family: Times;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
      the undersigned, thereunto duly authorized.</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z1a64170e839b4f47aee8770b894c6321" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 43%; vertical-align: bottom;">&#160;</td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td colspan="2" style="vertical-align: bottom;">
            <div style="color: #000000; font-family: 'Times New Roman'; font-weight: bold;">ALCON INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43%; vertical-align: bottom;">&#160;</td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.57%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 43%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman';"><font style="color: #000000;">Date:</font>&#160;<font style="color: #000000;">August 22, 2022</font></div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom;">
            <div style="color: #000000; font-family: 'Times New Roman';">By:&#160; <br>
            </div>
          </td>
          <td style="width: 43.57%; vertical-align: bottom; border-bottom: #000000 1.00pt solid;">
            <div style="color: #000000; font-family: 'Times New Roman';">/s/ David J. Endicott</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43%; vertical-align: bottom;">&#160;</td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td colspan="2" style="vertical-align: bottom;">
            <div style="color: #000000; font-family: 'Times New Roman';">Name: David J. Endicott</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43%; vertical-align: bottom;">&#160;</td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td colspan="2" style="vertical-align: bottom;">
            <div style="color: #000000; font-family: 'Times New Roman';">Title: Authorized Representative</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43%; vertical-align: bottom;">&#160;</td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.57%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 43%; vertical-align: bottom;">&#160;</td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.57%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 43%; vertical-align: bottom;">&#160;</td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.57%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 43%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman';"><font style="color: #000000;">Date:</font>&#160;<font style="color: #000000;">August 22, 2022</font></div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom;">
            <div style="color: #000000; font-family: 'Times New Roman';">By:&#160; <br>
            </div>
          </td>
          <td style="width: 43.57%; vertical-align: bottom; border-bottom: #000000 1.00pt solid;">
            <div style="color: #000000; font-family: 'Times New Roman';">/s/ Timothy C. Stonesifer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43%; vertical-align: bottom;">&#160;</td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td colspan="2" style="vertical-align: bottom;">
            <div style="color: #000000; font-family: 'Times New Roman';">Name: Timothy C. Stonesifer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43%; vertical-align: bottom;">&#160;</td>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td colspan="2" style="vertical-align: bottom;">
            <div style="color: #000000; font-family: 'Times New Roman';">Title: Authorized Representative</div>
          </td>
        </tr>

    </table>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1 - PRESS RELEASE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Skadden Arps
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <img src="logo.jpg">
  <div>
    <div>
      <div style="text-align: justify; color: #00AEEF; font-family: 'Open Sans'; font-size: 14pt; font-weight: bold;">MEDIA RELEASE&#160; &#8226;&#160; COMMUNIQUE AUX MEDIAS&#160; &#8226;&#160; MEDIENMITTEILUNG</div>
      <div><br>
      </div>
      <div style="color: #003595; font-family: 'Open Sans'; font-size: 17pt; font-weight: bold;">Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb98bf8adf0e84b4197ad56e9d75eecf6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 13.5pt; vertical-align: top; align: right; font-size: 12pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Open Sans'; font-size: 12pt;"><font style="font-weight: bold;">Builds on Alcon&#8217;s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
            </td>
          </tr>

      </table>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z43aac5519607446e8cb0df9a586be1a2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 13.5pt; vertical-align: top; align: right; font-size: 12pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Open Sans'; font-size: 12pt;"><font style="font-weight: bold;">Adds Rocklatan&#174; and Rhopressa&#174;, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates</font></div>
            </td>
          </tr>

      </table>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6c4d9ea627f44a0291c800939cb38dfe" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 13.5pt; vertical-align: top; align: right; font-size: 12pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Open Sans'; font-size: 12pt; font-weight: bold;">Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon&#8217;s core diluted EPS in 2024</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="color: #000000; font-family: 'Open Sans'; font-size: 12pt;"><font style="font-weight: bold;">Ad hoc announcement pursuant to Art. 53 LR</font>&#160;</div>
      <div><br>
      </div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;"><font style="font-weight: bold; color: #00AEEF;">GENEVA, Switzerland and DURHAM, NC August 22, 2022 </font>&#8211; Alcon (SIX/NYSE: ALC),&#160;the global leader in eye care dedicated to helping people
        see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, &#8220;Aerie&#8221;), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in-class ophthalmic therapies, today announced the companies have
        entered into a definitive merger agreement through which Alcon will acquire Aerie. This transaction affirms Alcon&#8217;s commitment to the ophthalmic pharmaceutical space and is expected to add broader pharmaceutical R&amp;D capabilities to Alcon&#8217;s
        existing commercial expertise, maximizing the value of its diversified portfolio.</div>
      <div><br>
      </div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;">Through the transaction, Alcon will add the commercial products Rocklatan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup><font style="font-style: italic; color: #090304;">(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%</font> and Rhopressa<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;<font style="font-style: italic;">(netarsudil ophthalmic
          solution) 0.02%</font><font style="font-style: italic; color: #090304;">, </font>as well as AR-15512, a Phase 3 product candidate for dry eye disease, and a pipeline of several clinical and preclinical <font style="color: #090304;">ophthalmic
          pharmaceutical </font>product candidates<font style="font-style: italic; color: #090304;">. </font>The transaction complements Alcon&#8217;s recent expansion into the ophthalmic pharmaceutical eye drop space, including acquisitions of the exclusive
        U.S. commercialization rights to Simbrinza<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>from Novartis in April 2021 and of Eysuvis<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
        and Inveltys<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> from Kala Pharmaceuticals, Inc. in May 2022.</div>
      <div><br>
      </div>
      <div style="color: #000000; font-family: 'Open Sans'; font-size: 10.5pt;">&#8220;Alcon is passionate about innovative treatments in eye care, especially in core disorders such as glaucoma and dry eye, which have significant patient impact,&#8221; said David
        Endicott, CEO of Alcon. &#8220;We have a 75-year history focused specifically on the eye and bring established expertise in development and commercial execution. Aerie is a natural fit with on-market and pipeline products, and R&amp;D capabilities that
        offer the infrastructure needed to expand our ophthalmic pharmaceutical presence. As we continue to broaden our portfolio across glaucoma, retina and ocular surface disease, we are excited to help even more patients see brilliantly.&#8221;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageNumberArea" style="text-align: right;"><font id="DSPFPageNumber" style="font-family: Tahoma, Geneva, 'sans-serif'; font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="color: #000000; font-family: 'Open Sans'; font-size: 10.5pt;">&#8220;We are excited to be joining Alcon, a recognized leader in eye care. I am so proud of the Aerie team and the innovation we&#8217;ve pioneered,&#8221; said Raj Kannan, Chief Executive
        Officer of Aerie Pharmaceuticals, Inc. &#8220;Alcon is the right strategic and financial partner to maximize the potential of Aerie&#8217;s commercial franchise and our growing portfolio of pipeline assets. Alcon&#8217;s global infrastructure, financial resources,
        and commercial capabilities will accelerate the standard of care by helping more patients have access to Aerie&#8217;s innovative products. I am confident that this combination with Alcon is in the best interest of patients and our shareholders.&#8221;</div>
      <div><br>
      </div>
      <div style="color: #000000; font-family: 'Open Sans'; font-size: 10.5pt;">Rocklatan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a fixed dose combination of the Rho kinase inhibitor, netarsudil, and a
        prostaglandin F2&#945; analogue, latanoprost, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a Rho kinase inhibitor indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. In most markets outside the U.S., commercialization rights for both products have been licensed
        to Santen SA and its affiliates.</div>
      <div><br>
      </div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;">The purchase price of $15.25 per share represents a premium of 37% to Aerie&#8217;s last closing price and represents an equity value of approximately $770 million. The transaction was approved by
        the board of directors of each company.</div>
      <div><br>
      </div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;">Aerie&#8217;s most recent financial guidance for total glaucoma franchise net product revenue is $130-140 million for full year 2022. The transaction is expected to be accretive to Alcon&#8217;s core
        diluted Earnings Per Share (EPS) in 2024. The transaction is anticipated to close in the fourth quarter of 2022, subject to the approval of Aerie&#8217;s stockholders and the satisfaction of customary closing conditions, including clearance under the
        Hart-Scott Rodino Antitrust Improvements Act. Alcon intends to fund the acquisition through short-term and long-term debt.</div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;"> <br>
      </div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;">J.P. Morgan acted as Alcon's financial advisor for the transaction, and Alcon&#8217;s legal advisor was Skadden, Arps, Slate, Meagher &amp; Flom LLP. Goldman Sachs &amp; Co. LLC acted as Aerie&#8217;s
        financial advisor for the transaction, and Aerie&#8217;s legal advisor was Fried, Frank, Harris, Shriver &amp; Jacobson LLP. </div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;"> </div>
      <div><br>
      </div>
      <div style="color: #003595; font-family: 'Open Sans'; font-size: 11pt; font-weight: bold;"><u>References</u></div>
      <div><br>
      </div>
      <div style="text-indent: 13.5pt; color: #000000; font-family: 'Open Sans'; font-size: 10.5pt;">1. Ophthalmology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030.</div>
      <div><br>
      </div>
      <div style="margin-bottom: 12pt; color: #003595; font-family: 'Open Sans'; font-size: 11pt; font-weight: bold;"><u>Cautionary Note Regarding Forward-Looking Statements</u></div>
      <div style="margin-right: 4.3pt; margin-bottom: 12pt; font-family: 'Open Sans'; font-size: 10.5pt;">This press release contains forward-looking statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform
        Act of 1995 related to the proposed acquisition of Aerie by Alcon. Forward-looking statements can be identified by words such as: &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;commitment,&#8221; &#8220;look forward,&#8221; &#8220;maintain,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;assume,&#8221;
        &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and similar references to future periods.</div>
      <div style="margin-bottom: 12pt; font-family: 'Open Sans'; font-size: 10.5pt;">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Alcon&#8217;s current beliefs, expectations and
        assumptions regarding the future of Alcon&#8217;s business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to
        predict such as: cybersecurity breaches or other disruptions of Alcon&#8217;s information technology systems; compliance with data privacy, identity protection and information security laws; Alcon&#8217;s ability to comply with the US Foreign</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageNumberArea" style="text-align: right;"><font id="DSPFPageNumber" style="font-family: Tahoma, Geneva, 'sans-serif'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div style="margin-bottom: 12pt;"><br>
      </div>
      <div style="margin-bottom: 12pt; font-family: 'Open Sans'; font-size: 10.5pt;">Corrupt Practices Act of 1977 and other applicable anti-corruption laws, particularly given that Alcon has entered into a three-year Deferred Prosecution Agreement with
        the U.S. Department of Justice; Alcon&#8217;s success in completing and integrating strategic acquisitions; <font style="color: #000000;">the completion of the proposed transaction on anticipated terms and timing, including obtaining stockholder and
          regulatory approvals, anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and
          management strategies for the management and other conditions to the completion of the transaction; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may
          prohibit, delay or refuse to grant approval for the consummation of the transaction; transaction costs; </font>the impact of a disruption in Alcon&#8217;s global supply chain or important facilities; the effect of the COVID-19 pandemic as well as
        other viral or disease outbreaks; global and regional economic, financial, legal, tax, political and social change; Russia&#8217;s war on Ukraine and the resulting global response; the commercial success of Alcon&#8217;s products and Alcon&#8217;s ability to
        maintain and strengthen Alcon&#8217;s position in Alcon&#8217;s markets; the success of Alcon&#8217;s research and development efforts, including Alcon&#8217;s ability to innovate to compete effectively; pricing pressure from changes in third party payor coverage and
        reimbursement methodologies; ongoing industry consolidation; Alcon&#8217;s ability to properly educate and train healthcare providers on Alcon&#8217;s products; the impact of unauthorized importation of Alcon&#8217;s products from countries with lower prices to
        countries with higher prices; Alcon&#8217;s reliance on outsourcing key business functions; changes in inventory levels or buying patterns of Alcon&#8217;s customers; Alcon&#8217;s ability to attract and retain qualified personnel; Alcon&#8217;s ability to service Alcon&#8217;s
        debt obligations; the need for additional financing through the issuance of debt or equity; Alcon&#8217;s ability to protect Alcon&#8217;s intellectual property; the effects of litigation, including product liability lawsuits and governmental investigations;
        Alcon&#8217;s ability to comply with all laws to which Alcon may be subject; effect of product recalls or voluntary market withdrawals; the implementation of Alcon&#8217;s enterprise resource planning system; the accuracy of Alcon&#8217;s accounting estimates and
        assumptions, including pension and other post-employment benefit plan obligations and the carrying value of intangible assets; the ability to obtain regulatory clearance and approval of Alcon&#8217;s products as well as compliance with any post-approval
        obligations, including quality control of Alcon&#8217;s manufacturing; legislative, tax and regulatory reform; the ability of Alcon Pharmaceuticals Ltd. to comply with its investment tax incentive agreement with the Swiss State Secretariat for Economic
        Affairs in Switzerland and the Canton of Fribourg, Switzerland; Alcon&#8217;s ability to manage environmental, social and governance matters to the satisfaction of Alcon&#8217;s many stakeholders, some of which may have competing interests; the impact of being
        listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to Alcon&#8217;s shareholders as a Swiss corporation compared to a U.S. corporation; and the effect of maintaining or losing Alcon&#8217;s foreign private
        issuer status under U.S. securities laws.</div>
      <div style="margin-bottom: 12pt; font-family: 'Open Sans'; font-size: 10.5pt;"> This press release also contains forward-looking statements related to Aerie, including statements regarding Aerie&#8217;s financial guidance for full year 2022 and Aerie&#8217;s
        commercial franchise, pipeline, preclinical studies and clinical trials. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change, and other factors beyond
        Aerie&#8217;s control and depend on regulatory approvals and macroeconomic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Aerie discusses many of these risks in
        greater detail under the heading &#8220;Risk Factors&#8221; in the quarterly and annual reports that Aerie files with the SEC.<br>
      </div>
      <div style="margin-right: 0.15pt; margin-bottom: 6pt; font-family: 'Open Sans'; font-size: 10.5pt;">Additional factors are discussed in Alcon&#8217;s filings with the United States Securities and Exchange Commission, including Alcon&#8217;s Form 20-F. Should one
        or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.
        Forward-looking statements in this press release speak only as of the date of its filing, and Alcon and Aerie assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageNumberArea" style="text-align: right;"><font id="DSPFPageNumber" style="font-family: Tahoma, Geneva, 'sans-serif'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div style="margin-bottom: 6pt;"><br>
      </div>
      <div style="color: #003595; font-family: 'Open Sans'; font-size: 10.5pt; font-weight: bold;"><u>Important Information and Where to Find It</u></div>
      <div style="margin-bottom: 12pt; font-family: 'Open Sans'; font-size: 10.5pt;">In connection with the proposed transaction between Alcon and Aerie, Aerie will file with the Securities and Exchange Commission (&#8220;SEC&#8221;) a proxy statement (the &#8220;Proxy
        Statement&#8221;), the definitive version of which will be sent or provided to Aerie stockholders. Aerie may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any other
        document which Aerie may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE
        DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement (when it is
        available) and other documents that are filed or will be filed with the SEC by Aerie through the website maintained by the SEC at <font style="color: #0000FF;"><u>www.sec.gov</u></font> or Aerie&#8217;s investor relations website at
        https://investors.aeriepharma.com.</div>
      <div style="color: #003595; font-family: 'Open Sans'; font-size: 10.5pt; font-weight: bold;"><u>Participants in the Solicitation</u></div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;">Alcon, Aerie and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.
        Information regarding Aerie&#8217;s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in Aerie&#8217;s proxy statement for its 2022 annual meeting of stockholders, which was
        filed with the SEC on April 26, 2022. Information regarding Alcon&#8217;s directors and executive officers is contained in Alcon&#8217;s annual report on Form 20-F for its fiscal year ended December 31, 2021, which was filed with the SEC on February 15, 2022.
        Aerie stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Alcon or Aerie directors and
        executive officers in the transaction, which may be different than those of Aerie stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the transaction. You
        may obtain free copies of these documents using the sources indicated above.</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #003595; font-family: 'Open Sans'; font-size: 10.5pt; font-weight: bold;"><u>About Alcon</u></div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;">Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than 75 years, we offer the broadest portfolio of products to enhance sight and improve
        people&#8217;s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24,000
        associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at&#160;<font style="color: #0000FF;"><u>www.alcon.com</u></font>.</div>
      <div><br>
      </div>
      <div style="color: #003595; font-family: 'Open Sans'; font-size: 10.5pt; font-weight: bold;"><u>About Aerie Pharmaceuticals, Inc.</u></div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;"><font style="color: #090304;">Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients
          with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). More information on Aerie Pharmaceuticals is available at www.aeriepharma.com. Aerie,
          Rocklatan</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="color: #090304;"> and Rhopressa</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="color: #090304;"> are registered trademarks of Aerie Pharmaceuticals, Inc.</font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageNumberArea" style="text-align: right;"><font id="DSPFPageNumber" style="font-family: Tahoma, Geneva, 'sans-serif'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div><br>
      </div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;"><font style="font-weight: bold; color: #003595;"><u>About Rocklatan</u></font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;"><font style="font-style: italic; color: #090304;">Rocklatan</font><sup style="color: #090304; font-style: italic; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-style: italic; color: #090304;"> (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% </font><font style="color: #090304;">is a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of
          elevated IOP in patients with open-angle glaucoma or ocular hypertension. Launched in the United States in May 2019, it is a fixed-dose combination of Rhopressa</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="color: #090304;"> and latanoprost ophthalmic solution (0.005%), a commonly prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. In clinical trials of Rocklatan</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="color: #090304;">, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about
          Rocklatan</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="color: #090304;">, including the product label, is available at </font><font style="color: #0000FF;"><u>www.rocklatan.com</u></font>.</div>
      <div><br>
      </div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;"><font style="font-weight: bold; color: #003595;"><u>About Rhopressa</u></font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
      <div style="font-family: 'Open Sans'; font-size: 10.5pt;"><font style="color: #090304;">Rhopressa</font><sup style="color: #090304; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="color: #090304;">&#160;</font><font style="font-style: italic; color: #090304;">(netarsudil ophthalmic solution) 0.02%, </font><font style="color: #090304;">a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular
          pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="color: #090304;">, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rhopressa</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="color: #090304;">, including the product label, is available at www.rhopressa.com</font>.</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="color: #1F497D; font-family: 'Open Sans'; font-size: 11pt; font-weight: bold;">Connect with us on</div>
      <div><br>
      </div>
      <div style="color: #1F487C; font-family: 'Open Sans'; font-size: 11pt; font-weight: bold;"><img src="image2.jpg" height="38" width="38">&#160; &#160; <img src="image3.jpg" height="38" width="38"></div>
      <div><br>
      </div>
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd20cd3a1cb7849169847948bb52e5703" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 35%; vertical-align: top;">
                <div style="text-align: justify; color: #00AEEF; font-family: 'Open Sans'; font-size: 11pt; font-weight: bold;"><u>Investor Relations</u></div>
                <div style="text-align: justify; color: #000000; font-family: 'Open Sans'; font-size: 11pt;">Daniel Cravens</div>
                <div style="text-align: justify; color: #000000; font-family: 'Open Sans'; font-size: 11pt;">Allen Trang</div>
                <div style="text-align: justify; color: #000000; font-family: 'Open Sans'; font-size: 11pt;">+ 41 589 112 110 (Geneva)</div>
                <div style="text-align: justify; color: #000000; font-family: 'Open Sans'; font-size: 11pt;">+ 1 817 615 2789 (Fort Worth)</div>
                <div style="text-align: justify; font-family: 'Open Sans'; font-size: 11pt;">investor.relations@alcon.com</div>
              </td>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: justify; color: #00AEEF; font-family: 'Open Sans'; font-size: 11pt; font-weight: bold;"><u>Media Relations</u></div>
                <div style="text-align: justify; color: #000000; font-family: 'Open Sans'; font-size: 11pt;">Steven Smith</div>
                <div style="text-align: justify; color: #000000; font-family: 'Open Sans'; font-size: 11pt;">+ <font style="font-size: 12pt;">41 589 112 111</font> (Geneva)</div>
                <div style="text-align: justify; color: #000000; font-family: 'Open Sans'; font-size: 11pt;">+ 1 682 <font style="font-size: 12pt;">551 8057</font> (Fort Worth)</div>
                <div style="text-align: justify; font-family: 'Open Sans'; font-size: 11pt;">globalmedia.relations@alcon.com</div>
              </td>
            </tr>

        </table>
        <div style="margin-bottom: 8pt;"><br>
        </div>
        <div style="margin-bottom: 8pt;"><br>
        </div>
        <div style="margin-bottom: 8pt;"><br>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: right;"><font id="DSPFPageNumber" style="font-family: Tahoma,Geneva,'sans-serif'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: %H# 2(  A$! Q$!_\0
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&**S+/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image3.jpg
<TEXT>
begin 644 image3.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: %H# 2(  A$! Q$!_\0
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,(1@K104445F6?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
M 0(#! 4&!P@)"@L0  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B
M<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'
M2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ
M\?+S]/7V]_CY^A$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B
M,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'
M2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:
MHJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ
M\O/T]?;W^/GZ_\  $0@ QP,3 P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ [.OH
MCS@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#H(?"NISQK-' 2CJ&4[XP2",@X+
MAN1V(S6#K03LWJO)_P"1IR2WL8!!!P>"*W,S4T[1+S559K2/S A ;YD7!/3[
MS+^E9RJ1IZ2=OD_T*47+8IWEG+82M;W"[)$QE<@XR 1RI(Z$=#51DI+FCL)K
MET96JA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M 7,#1*A)7#LP.1P>B$?K2G6C3?*[W\O^'!0<E=&A;^ [Z5-SM'$><*22?J<
M@9_/U Z5F\1!.R392ILY;4=.GTN8V]PNUQSQR"#T*GN#_P#6.#73&2FN:.QF
MTXNS*-62% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &GI^G?;DG?=L^SQ&3&W.[';
MJ,?7GZ5G*7*TK;NQ25[^1F5H2% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M,X.NTP"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@"P;N<E6,C[H@ AW-E .@4Y^4#L!BERK566N^FX[
MB+<S))YRNXE))WAB'R>IW9SDYYYYHLK6LK=N@7ZB"YE56C#N$D.74,<,>N6&
M<'\<T66]EIMY ()Y%C,(=A&QR4#':3ZE<X)X'.,\465[VU[AY#C=3,4)D<F(
M 1DLWR = G/RXP,8QBBR5]%KOY^H7'QWUQ$6,<LB&0Y;:[#<3U+8/)/J:7*G
MNEIMH%VAOVN?G]X_S+L;YFY0<!3SRH'&T\>U/E79=]NO<+CDO;B)/*2618SG
M*!V"\]?E!QSWXYI<J;NTK][!=[")>SQQ^2DDBQG.4#L%YZ_*#CGOQ1RJ][*_
M>P7>Q&9I"@B+-Y8.X)D[0?4+TS[XS3LKWMKW%Y$C7D[$L9)"67827;)3^X3G
ME?\ 9/'M1RI=%WVZ]QW8L5[<0)Y<<LB(>JJ[!3GKP"!S2<4]6E?T"[0D=[<0
MH8HY9$C/55=@ISU^4''/THY4W=I7] N]B+SGV>5N;R]V[9D[=V,;MO3=CC.,
MXXJK*]^O<7D2?:Y_,$WF/Y@& ^YMP&,8#9SC!QC/3CI2Y5:UE;M8=RO3$% !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M^&2^\AI&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MUZC\QQ4VL=T:D)_"UZ=?N*](U"@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H M0V4T_W%./4\#_ #]*=C"=6%/XGKV6K->'
M1E7F5L^R\#\^O\JJQP3Q3VIJWF_\C5BMXX.(U"^_?\^M5:QPRG*?Q-O\ON)J
M9F% %RWT^>Z_U2$CUQ@?F<#]:RE4A#XFEY=?N-X4:E3X(M^>R^]F];^&'/,[
MA?9>3^? _G7%+%):05_-Z'I0P$GK4DEY+5_>;MOHMK;]$WD=WY_3I^E<4J]2
M76R\M/\ @GI0PM*G]F[[RU_X'X&HJA!A0 !V'%<_J=J26BT%I#"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M3AP5/N*D[HR4M8M/T(Z104 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % #TC:0[4!8^PIDMJ*O)I+S-6#1Y'YD(0>@Y/\ @*=CAGBHQT@KO[D:
M\%A#;\JN3ZMR?\!5VL>?.M.>C=EV6A=IG.% %FWLYKDXB0M]!Q^)Z#\36<IQ
MA\32-84YU-(1;_+[]CH+;PR[<SL$'HO)_/H/UKAEBDM(*_F]#U*> D]:LDO)
M:O[]OS.@MM'M;7E4#'U;D_ET'X"N&5:<]W9=EH>I3PU*GM&[[O7_ (!I@8X%
M<YV!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % $<D*3#;(H8>A -4FXZQ;7H1*,9*TDF
MO-&)<^';>;F/,1]N1^1Y_(BNR&)G'XO>7W/[SSIX*G+6%XORU7W/_,Y^Y\/W
M,'* 2+_L]?R//Y9KNAB(2T?NOS_S/+J8.K3UBN9>6_W?Y&(\;1G# J1V(Q76
MFGJCSVG%V:L^ST&TQ#617&& (]#S0--QUB[/R,N?2(I.8\QG\Q^7^!J;';#$
MSCI+WE]S,>?3IH.<;E]5Y_3K4VL>A"O">E[/L]/^ 4:DZ@H * "@ H * "@
MH * "@ H * "@ H * "@ H LP6DMQ]Q3CU/ _.G8QG4A3^)_+K]QLP:.B\RG
M<?0<#\^I_2JL>=/%-Z4U;S>_^1K1Q+$-J */:JV."4G)WDVWYDE,D<B,YPH)
M)[ 9I-I:O1#2;=DKOLC<M?#UQ/S)B)?]KK^0_KBN.>)A#2/O/RV^\]&G@JD]
M9>XO/?[O\SI+70;:WY8>8WJW3\AQ^>:X)XB<M%[J\O\ ,]:G@Z5/5KF?GM]V
MWYFRJA!A0 !V' KDO?5GH)):+1"TAA0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 03VL5R,2J&^HY'T/4?A5QG*&L6T93IPJ*TXI^IS]UX9C?F!BA]&Y
M'Y]1^.:[H8IK2:OYK1GEU,!%ZTG;R>J^_?\ ,YNZTJXL^70[?[PY'YCI^.*]
M"%6$_A>O9Z,\FIAZE+XHZ=UJOZ]3.Z5N<H4 5)[**X^^O/J.#_GZTK&\*LZ?
MPO3L]48T^CNG,1WCT/!_P/Z5-NQZ,,5%Z37*^^Z,ET:,[6!4^AXJ3N34E>+N
MO(;2*"@ H * "@ H * "@ H * "@ H O6^G37'(&U?5N/R'4U5CFG7A3TO=]
MD;=OI<4/+?.WOT_+_'-5:QYD\1.>D?=7EO\ >:0&.!Q5'&+0!;MK&:[.(E+>
M_8?4GBLI3C3^)V_/[C:G2G5TIQ;\^GW['2VGAD##7#9_V5_J3_0?C7GSQ72F
MOF_\CUZ> ZU9?*/^9TEO:0V@Q$H7W'7\3U-<$IRGK)MGKPI0I*U.*7Y_?N6*
MS-0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,NZT:
MVNN2NQO[R\?IT/Y9KIA7G3T3NNSU.*IA:575JS[K3_@',W?AR>'F'$J^W#?D
M?Z$_2O1AB8RTE[K_  /'J8*I#6G[R^Y_=_D8#QM$=K@J1U!&*[4T]5L>8TXN
MTDT^ST&4Q$4D*3#:X##WI%QE*#O%M&/<:,.L)Q_LM_0_XU-NQZ$,5TJ+YK_(
MQ98)(#B12O\ +\#TJ=CT8SC-7@[D5(T"@ H * "@ H * "@#1M],EGY(V+ZG
MK^ __556.2>(A3T6K[+_ #-VWT^*WY W-ZM_0=!56L>7.O.II>R[(O51S!0!
MJ6>CW%YRJ[5_O-P/P[G\ :YIUH4]&[OLCLI8:I5U2LN[T7^;.JL_#T%OS+^]
M;WX7\N_XD_2O.GB9RTC[J_'[SV:6"IT]9^\_/;[O\S=50@VJ  .@' KB;OJS
MTTDM%HA:0PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M7*=P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 UT60%6 8'J",BFFUJM&)I25FKKLSG+[PY
M'+EK<[&_NG[OX'J/U'TKT*>*<=*FJ[]?^">15P,9>]1?*^SV_P T<C<V<MFV
MV52OIZ'Z'H?PKTXSC-7@[GAU*<Z3Y9IK\GZ,K5H9!0!ZY7RY]R% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!'+"DR[)%#*>Q&:I2<7>+LR)1C-<L
MDFNS.6O_  V.7M3C_8;^A_H?SKTJ>*Z5/O7ZK_(\6M@?M4'_ -NO]'_G]YRC
31,A*D<C@UZ:UU1XC7*[/='__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
